接受苯扎贝特治疗的高胆固醇血症患者低密度脂蛋白降低，高密度脂蛋白载脂蛋白升高。

Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.

作者信息

Mordasini R, Riesen W, Oster P, Keller M, Middelhoff G, Lang P D

出版信息

Atherosclerosis. 1981 Oct;40(2):153-8. doi: 10.1016/0021-9150(81)90033-2.

Abstract

The effect of bezafibrate on serum lipids, lipoproteins and the apoproteins A-I, A-II and B was studied in 18 patients with primary hypercholesterolaemia. Total cholesterol was lowered by 20% (P less than 0.05), LDL-cholesterol by 24% (P less than 0.05), and apo B by 14% (P less than 0.05), which is comparable to the effect obtained with anion exchange resins but with far fewer side-effects. HDL increased significantly during bezafibrate treatment both by measurement of HDL-cholesterol (+54%, P less than 0.05) and by the determination of HDL-apoproteins A-I (+ 19%, P less than 0.05) and A-II (+ 23%, P less than 0.05). This increase of HDL and the decrease of triglycerides was maintained for 6 weeks of placebo treatment after cessation of bezafibrate, while serum total and LDL cholesterol as well as apo B returned to their baseline levels.

摘要

在18例原发性高胆固醇血症患者中研究了苯扎贝特对血脂、脂蛋白以及载脂蛋白A-I、A-II和B的影响。总胆固醇降低了20%（P<0.05），低密度脂蛋白胆固醇降低了24%（P<0.05），载脂蛋白B降低了14%（P<0.05），这与使用阴离子交换树脂所获得的效果相当，但副作用要少得多。在苯扎贝特治疗期间，通过测量高密度脂蛋白胆固醇（升高54%，P<0.05）以及测定高密度脂蛋白载脂蛋白A-I（升高19%，P<0.05）和A-II（升高23%，P<0.05），高密度脂蛋白显著升高。在停用苯扎贝特后，进行6周的安慰剂治疗期间，高密度脂蛋白的这种升高以及甘油三酯的降低得以维持，而血清总胆固醇、低密度脂蛋白胆固醇以及载脂蛋白B则恢复到基线水平。